Detecting HR-HPV is now easier, faster, and more reliable than before.
Mía by XytoTest® is a reliable, trustworthy all-in-one proprietary molecular screening system for cervical cancer prevention, comprising HR-HPV DNA detection and triage with E6/E7 mRNA* biomarkers.
* Messenger ribonucleic acid
A patented, clinically proven three-step system for comprehensive Cervical Cancer prevention
1 Centers for Disease Control and Prevention
Having high-risk Human Papillomavirus is NOT THE SAME as having Cervical Cancer.
Most HPV infections are asymptomatic and short-lasting and are cleared by the body’s own immune system. However, infections caused by one or more of the 14 high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) can be long-lasting and lead to precancerous lesions, which can develop into Cervical Cancer if left untreated.
Cervical Cancer is the only cancer that is 100% preventable.
World figures: 2
2 World Health Organization. International Agency for Research on Cancer IARC. December 31, 2018
Triage – with E6/E7 mRNA biomarkers that detect seven specific HR-HPV genotypes – helps women avoid unnecessary treatment. 3 Overexpression of E6/E7 oncoproteins in active HR-HPV infections also guides decisions regarding future disease risk. 4
3 Massimo Origoni et al, Cancer Medical science. Milan, Italy April 29, 2015
4 Virol J. 2018 Mar 27;15(1):52. doi: 10.1186/s12985-018-0957-z.
A negative test result does not confirm the absence of cervical cancer. Patients with a negative test result should discuss with their doctor when they need to be tested again. False-positive and false-negative results can occur.
This procedure can be performed by a healthcare professional or as a self-sampling technique by the patient herself.
Check that the barcodes match on all kit items (informed consent, test tube, and safe storage bag).
After completing all the fields in the informed consent form, wash hands and/or put on gloves before using the device.
With the patient lying on her back with her knees flexed, take the device out of the packet, remove the protective cap, and discard it.
Separate the labia and without a speculum carefully insert the device into the vagina until the rim of the device base touches the skin. Rotate the device three times (through 360°) in a clockwise or counterclockwise direction.
Carefully withdraw the device from the vagina and immediately place it in the transport tube provided. Close the tube. Place the tube and completed informed consent form in the safe storage bag.
Send the sample for testing as soon as possible, following the laboratory’s shipping instructions.
Yes. More than two-thirds of young adult women get HPV within two years of becoming sexually active.
Mía by XytoTest® is a molecular test suitable for all sexually active women over the age of 25.
No. Mía by XytoTest® is a user-friendly device that is not painful or even uncomfortable.
Mía by XytoTest® is designed for use without a speculum to achieve a more even, representative sample of the whole of the vagina, and to collect more cervicovaginal cells.
Yes. Mía by XytoTest® can be used during a woman’s period, although avoiding the first three days of heavy blood flow will prevent getting clots in the sample.
Yes. Ovules, gels, creams, lubricants, and vaginal douches should not be used for 24 hours prior to the sampling procedure.
The result indicates the presence or absence of one or more of the 14 HR-HPV genotypes. Genotypes 16 and 18 are reported separately, while the 12 other genotypes are reported as a pool.
If the HR-HPV DNA test is positive, a second test is performed to identify E6/E7 mRNA in HR-HPV genotypes 16, 18, 31, 33, 45, 52, and 58. This co-test shows whether the HR-HPV infection has already triggered oncogenic activity.
Having an HR-HPV infection is not the same as having Cervical Cancer. A positive HR-HPV test and a negative E6/E7 mRNA test simply warns that the virus exists. A healthcare professional should assess the results together with other tests and the patient’s medical record.
A positive result in both tests shows that the HR-HPV infection has triggered oncogenic activity and that this is not simply a passing infection. A healthcare professional should assess the results together with other tests and the patient’s medical record.
A test is recommended every 3-5 years for patients with negative molecular tests, known medical records, and a single sexual partner. However, healthcare professionals should decide on test frequency.
We develop medical devices and safe, state-of-the-art molecular technologies that empower you to take control of your health through prevention.
Learn about the new technologies we’re developing for personalized medicine.
Have Questions? Our team is happy to answer any questions you may have.
